Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 0.51 |
| ▸ | HTR1A | P08908 | 17/20 | 0.51 |
| ▸ | HTR2A | P28223 | 17/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15545155 | 0.89 | DRD2 (0.49) | DRD2HTR1AHTR2A | |
| SCHEMBL15547269 | 0.89 | DRD2 (0.52) | DRD2HTR1AHTR2A | |
| SCHEMBL15545026 | 0.88 | DRD2 (0.65) | DRD2HTR1AHTR2A | |
| SCHEMBL20696671 | 0.88 | DRD2 (0.51) | DRD2HTR1AHTR2A | |
| SCHEMBL16559724 | 0.86 | DRD2 (0.58) | DRD2HTR1AHTR2A | |
| SCHEMBL16559686 | 0.84 | DRD2 (0.51) | DRD2HTR1AHTR2A | |
| SCHEMBL15532853 | 0.83 | DRD2 (0.45) | DRD2HTR1AHTR2A | |
| SCHEMBL15532351 | 0.83 | DRD2 (0.45) | DRD2HTR1AHTR2A | |
| SCHEMBL16559700 | 0.81 | DRD2 (0.53) | DRD2HTR1AHTR2A | |
| SCHEMBL15533075 | 0.80 | DRD2 (0.54) | DRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847193-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190031685-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-01-31 | — | — | US | disclosed |
| US-20190031685-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-01-31 | — | — | US | disclosed |
| US-9951088-B2 | D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951088-B2 | D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951088-B2 | D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-2847193-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-03-12 | — | — | US | disclosed |
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-03-12 | — | — | US | disclosed |
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-03-12 | — | — | US | disclosed |
| WO-2013169964-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013169964-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, SNCA, KYNU | DRD2 53/4885HTR1A 24/4885HTR2A 16/4885 |
| US-20190031685-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, SNCA, KYNU | DRD2 53/4885HTR1A 24/4885HTR2A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.